Response rate as criterium to evaluate chemotherapy in non-small cell lung cancer

A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer

“…The current multi-institutional phase II trial of CPT-11 and cisplatin in combination for advanced NSCLC demonstrates the encouraging response rate of 52%, confirming the preliminary response rate of 54% obtained in a previous phase I trial in advanced NSCLC (Masuda et al, 1992b). A response rate of 30-40%, a median survival time of 6-9 months, and a 1-year survival of approximately 20% are commonly seen in treatments with cisplatin-based regimens, usually in combination with etoposide or a vinca alkaloid (Cellerino et al, 1990;Splinter, 1991;Bunn, 1992). Therefore, the response rate obtained in this study is in the upper range of the reported trials in NSCLC among combination chemotherapy regimens currently in use.…”

A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer

“…The current multi-institutional phase II trial of CPT-11 and cisplatin in combination for advanced NSCLC demonstrates the encouraging response rate of 52%, confirming the preliminary response rate of 54% obtained in a previous phase I trial in advanced NSCLC (Masuda et al, 1992b). A response rate of 30-40%, a median survival time of 6-9 months, and a 1-year survival of approximately 20% are commonly seen in treatments with cisplatin-based regimens, usually in combination with etoposide or a vinca alkaloid (Cellerino et al, 1990;Splinter, 1991;Bunn, 1992). Therefore, the response rate obtained in this study is in the upper range of the reported trials in NSCLC among combination chemotherapy regimens currently in use.…”

Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life

“…In phase III clinical trials, survival is generally the preferred [17][18][19][20][21]. However, survival results from large trials can only be used for treatment selection recommendations, not for ongoing decisions as to whether to continue chemotherapy or not.…”

A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer

“…The current multi-institutional phase II trial of CPT-11 and cisplatin in combination for advanced NSCLC demonstrates the encouraging response rate of 52%, confirming the preliminary response rate of 54% obtained in a previous phase I trial in advanced NSCLC (Masuda et al, 1992b). A response rate of 30-40%, a median survival time of 6-9 months, and a 1-year survival of approximately 20% are commonly seen in treatments with cisplatin-based regimens, usually in combination with etoposide or a vinca alkaloid (Cellerino et al, 1990;Splinter, 1991;Bunn, 1992). Therefore, the response rate obtained in this study is in the upper range of the reported trials in NSCLC among combination chemotherapy regimens currently in use.…”

Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life

“…In phase III clinical trials, survival is generally the preferred [17][18][19][20][21]. However, survival results from large trials can only be used for treatment selection recommendations, not for ongoing decisions as to whether to continue chemotherapy or not.…”

A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer

“…The current multi-institutional phase II trial of CPT-11 and cisplatin in combination for advanced NSCLC demonstrates the encouraging response rate of 52%, confirming the preliminary response rate of 54% obtained in a previous phase I trial in advanced NSCLC (Masuda et al, 1992b). A response rate of 30-40%, a median survival time of 6-9 months, and a 1-year survival of approximately 20% are commonly seen in treatments with cisplatin-based regimens, usually in combination with etoposide or a vinca alkaloid (Cellerino et al, 1990;Splinter, 1991;Bunn, 1992). Therefore, the response rate obtained in this study is in the upper range of the reported trials in NSCLC among combination chemotherapy regimens currently in use.…”

Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life

“…In phase III clinical trials, survival is generally the preferred [17][18][19][20][21]. However, survival results from large trials can only be used for treatment selection recommendations, not for ongoing decisions as to whether to continue chemotherapy or not.…”